Showing 1731-1740 of 2029 results for "".
- Study: Skin of Color Patients Are Under-represented in Cosmetic Clinical Trialshttps://modernaesthetics.com/news/study-skin-of-color-patients-are-under-represented-in-cosmetic-clinical-trials/2473221/There’s a lack of ethnic/racial diversity in industry-sponsored aesthetic trials, according to new research in the April 2022 issue of Lasers in Surgery and Medicine. Researchers, led by Lisa Akintilo MD, MPH a current PGY-4 dermatology resident at New York
- Suneva's Silhouette InstaLift Recognized with New Beauty Awardhttps://modernaesthetics.com/news/sunevas-silhouette-instalift-recognized-with-new-beauty-award/2473219/Suneva Medical, Inc.'s non-surgical thread lift, Silhouette InstaLift®, is the Best Thread Lift Treatment in NewBeauty's 2022 Beauty Awards. It uses collagen-stimulating absorbable sutures that offer patients immediate and lasting results with minimal recovery time.
- Happy 20th Birthday Botox Cosmetic!https://modernaesthetics.com/news/happy-20th-birthday-botox-cosmetic/2473218/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Endymed's US Subsidiary Taps Bill Scott as New Presidenthttps://modernaesthetics.com/news/endymeds-us-subsidiary-taps-bill-scott-as-new-president/2473215/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- Jeune Aesthetics Shares Positive Clinical Phase 1 Data for Investigational Gene-based Treatment to Address the Underlying Biology of Aging Skinhttps://modernaesthetics.com/news/jeune-aesthetics-shares-positive-clinical-phase-1-data-for-investigational-gene-based-treatment-to-address-the-underlying-biology-of-aging-skin/2473210/Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc. shared positive proof-of-concept efficacy data from Cohort 2 of its PEARL-1 study of KB301, Jeune Aesthetics’ lead candidate for the treatment of aesthetic skin conditions. “We are pleased to see
- Cynosure and Jeisys Medical Japan Expand Partnershiphttps://modernaesthetics.com/news/cynosure-and-jeisys-medical-japan-expand-partnership/2473209/Cynosure LLC’s subsidiary Cynosure KK has entered into a distribution partnership with Jeisys Medical KK, a subsidiary of Jeisys Medical Inc. in Japan. Under the terms of the agreement, Jeisys Medical will have exclusive distribution rights for products within Cynosure&
- Newsweek OpEd: Senator, Modern Aesthetics® Magazine Contributor Address "No Surprises Act"https://modernaesthetics.com/news/newsweek-oped-senator-modern-aesthetics-magazine-contributor-address-no-surprises-act/2473207/Although surprise bills are one of the biggest drivers of medical bankruptcy in America, the "No Surprises Act" (NSA) is being overlooked, say Jonathan Kaplan, MD and Sen. William Cassidy, MD (R, Louisiana) in a new
- This National Peel Day, PCA Skin Asks, #HowYouPeelinhttps://modernaesthetics.com/news/this-national-peel-day-pca-skin-asks-howyoupeelin/2473206/PCA SKIN® wants to know #HowYouPeelin, as the company celebrates the third annual National Peel Day, Thursday, highlighting their latest peel innovation, new partnership, special promotion for accounts, and a host of social media activities. National Peel Day is recognize
- The Beauty Health Company Introduces HydraFacial Syndeo Delivery Systemhttps://modernaesthetics.com/news/the-beauty-health-company-introduces-hydrafacial-syndeo-delivery-system/2473205/The Beauty Health Company is rolling out the HydraFacial Syndeo, a digital device that aims to enhance the consumer and provider experience. “As a category creator, we deliver beauty health experiences every day that re-invent our consumer’s relationship with their ski
- Revance Resubmits BLA for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-resubmits-bla-for-daxibotulinumtoxina/2473204/Revance Therapeutics, Inc. has resubmitted its Biologics License Application (BLA) to FDA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The submission is in response to the Complete Response Letter (CRL) issued by FDA in October 2021. The